Atai Beckley N.V.
atai Beckley N.V. was a Dutch public limited company (naamloze vennootschap) registered with the Netherlands Chamber of Commerce (KvK) under number 80299776, with its registered office at Prof. J.H. Bavincklaan 7, 1183 AT Amstelveen, Netherlands. The company traded under this name from 5 November 2025 until its dissolution on 30 December 2025, and is recorded in the Dutch registry as inactive.
atai Beckley N.V. was previously named ATAI Life Sciences N.V., incorporated in the Netherlands on 10 September 2020. It operated as a clinical-stage biopharmaceutical company developing psychedelic-inspired and related compounds intended to treat depression, anxiety, addiction and other mental health disorders. Its ordinary shares listed on the Nasdaq Global Market under the ticker ATAI from June 2021, following an initial public offering that raised approximately 231.6 million US dollars in net proceeds.
On 5 November 2025, the company completed its acquisition of the remaining issued share capital of Beckley Psytech Limited, a United Kingdom-based clinical-stage company developing short-duration psychedelic therapies, under a share purchase agreement dated 2 June 2025. In connection with this transaction, the company changed its name from ATAI Life Sciences N.V. to atai Beckley N.V.
Shareholders approved a corporate redomiciliation from the Netherlands to the United States at an extraordinary general meeting on 4 November 2025. On 30 December 2025, atai Beckley N.V. merged into atai Life Sciences Luxembourg S.A., which then converted into a Delaware corporation named AtaiBeckley Inc. Outstanding ordinary shares of atai Beckley N.V. were exchanged on a one-for-one basis for common stock of AtaiBeckley Inc., which now trades on Nasdaq under the ticker ATAI as the successor issuer. As a result, atai Beckley N.V. no longer operates as an active Dutch legal entity, consistent with its inactive status in the KvK register.
- Company fundamentals
- Corporate linkage & group structures
- Digitized company financials
- Firmographics — websites, social profiles, revenue and employee estimates
Shareholders
5
Shareholders of atai Beckley N.V.
As a Nasdaq-listed company, atai Beckley N.V. (formerly ATAI Life Sciences N.V.) was subject to U.S. securities disclosure rather than a published Dutch shareholder register. Reportable institutional holders identified in connection with the ATAI ticker include Adage Capital Partners GP, L.L.C. (approximately 17.9%), Ally Bridge Group (NY) LLC (approximately 7.5%), ARK Investment Management, LLC (approximately 6.6%), T. Rowe Price Investment Management, Inc. (approximately 6.4%) and Marshall Wace LLP (approximately 3.5%), among further institutional holders. These figures reflect major reportable holdings rather than the company’s complete shareholder base. The underlying data is dated around September 2026, which is after the Dutch legal entity had already converted into its Delaware successor, AtaiBeckley Inc., on 30 December 2025. atai Beckley N.V.’s outstanding ordinary shares were exchanged one-for-one for common stock of that successor at conversion, so ownership data dated after that conversion relates to AtaiBeckley Inc. rather than to the dissolved Dutch entity itself.
Data availability
Shareholder information for this entity is major shareholders only and historical: the Dutch legal entity ceased to exist on 30 December 2025, and subsequent ownership records apply to its Delaware successor, AtaiBeckley Inc., not to atai Beckley N.V. directly.
Sources
- Netherlands Chamber of Commerce (KvK), company register, retrieved 18 September 2026, https://www.kvk.nl
- Northdata, Atai Beckley N.V., Amstelveen (KvK 80299776), retrieved 18 September 2026, https://www.northdata.com/Atai+Beckley+N.V.,+Amstelveen/KVK+80299776
- GlobeNewswire, AtaiBeckley Completes Redomiciliation to the United States, 30 December 2025, https://www.globenewswire.com/news-release/2025/12/30/3211650/0/en/AtaiBeckley-Completes-Redomiciliation-to-the-United-States.html
| Shareholder | Type | Holding | Source Document |
|---|---|---|---|
| Adage Capital Partners GP L.L.C. | 17.9% | Netherlands Chamber of Commerce (KvK) | |
| Ally Bridge Group (NY) LLC | 7.5% | Netherlands Chamber of Commerce (KvK) | |
| ARK Investment Management, LLC | 6.6% | Netherlands Chamber of Commerce (KvK) | |
| T. Rowe Price Investment Management, Inc. | 6.4% | Netherlands Chamber of Commerce (KvK) | |
| Marshall Wace LLP | 3.5% | Netherlands Chamber of Commerce (KvK) |
Officers
16
Directors and officers of atai Beckley N.V.
Company records disclose five active executive officers for this entity, covering scientific, medical, research and development, investment and venture, and investor-relations functions. Two appointments are independently verifiable from a primary source: Glenn Short, Ph.D., was named Chief Scientific Officer and Kevin Craig, M.D., was named Chief Medical Officer, both effective from leadership changes announced on 10 January 2025, before the company’s name change to atai Beckley N.V. Dr Craig had previously served as Senior Vice President of Clinical Development from July 2023. The remaining disclosed officer roles (Chief Research & Development Officer, Vice President of Investment & Venture Management, and Senior Director of Investor Relations) are consistent with the company’s known executive structure but are not independently re-verified here. Correspondence records list the Netherlands for these officers; this is a correspondence address only and does not indicate nationality or country of residence for any individual. Nationality is not disclosed for any officer.
Data availability
Officer information reflects company-disclosed executive officers current only as of the most recent registry sync. It does not represent a Dutch KvK statutory management-board filing, and historical appointment or resignation dates are not available. Nationality is not publicly disclosed for these individuals.
Sources
- atai Life Sciences, Key Leadership Appointments announcement, 10 January 2025, https://www.globenewswire.com/news-release/2025/01/10/3007542/0/en/atai-Life-Sciences-Announces-Key-Leadership-Appointments-as-it-Advances-its-Pipeline-of-Novel-Psychedelic-Therapeutics-for-Mental-Health.html
- Netherlands Chamber of Commerce (KvK), company register, retrieved 18 September 2026, https://www.kvk.nl
Registry feed — rows exactly as filed with Netherlands Chamber of Commerce (KvK), including entries the profile above does not cover.
Group Structure
Group structure of atai Beckley N.V.
atai Beckley N.V. (formerly ATAI Life Sciences N.V.) was the Nasdaq-listed top entity of the atai corporate group rather than a subsidiary of another company. On 5 November 2025 it completed the acquisition of the remaining share capital of Beckley Psytech Limited, a United Kingdom clinical-stage company, under a share purchase agreement dated 2 June 2025, and changed its name to atai Beckley N.V. in connection with the transaction. Following shareholder approval on 4 November 2025, atai Beckley N.V. merged on 30 December 2025 into atai Life Sciences Luxembourg S.A. (Luxembourg), which then converted into AtaiBeckley Inc., a Delaware corporation. Outstanding shares converted one-for-one into AtaiBeckley Inc. common stock, which continues to trade on Nasdaq under the ticker ATAI. As a result, atai Beckley N.V. no longer exists as a separate legal entity; the group is now held through its Delaware successor.
Verified corporate relationships
| Entity | Country | Registration number | Relationship | Ownership | Status | Information date |
|---|---|---|---|---|---|---|
| Beckley Psytech Limited | United Kingdom | Not disclosed | Direct subsidiary (acquired) | Full remaining share capital acquired | Historical (absorbed into successor group) | 5 Nov 2025 |
| atai Life Sciences Luxembourg S.A. | Luxembourg | Not disclosed | Merger vehicle in redomiciliation | Ownership percentage not disclosed | Historical (converted into Delaware entity) | 30 Dec 2025 |
| AtaiBeckley Inc. | United States (Delaware) | Not disclosed | Successor entity via merger and conversion | 1:1 share exchange | Current ultimate entity of the group | 30 Dec 2025 |
Recent structural changes
- 5 November 2025: Completed acquisition of Beckley Psytech Limited and changed name to atai Beckley N.V.
- 4 November 2025: Shareholders approved redomiciliation from the Netherlands to the United States.
- 30 December 2025: Completed merger and conversion into AtaiBeckley Inc. (Delaware); the Dutch entity ceased to exist.
Data availability
Corporate-linkage information is historical: atai Beckley N.V. ceased to exist as a legal entity on 30 December 2025, and its group structure is now maintained under its Delaware successor, AtaiBeckley Inc.
Sources
- SEC, Form 8-K, atai Beckley N.V., 2025, https://www.sec.gov/Archives/edgar/data/1840904/000114036125040429/ef20058318_8k.htm
- GlobeNewswire, AtaiBeckley Completes Redomiciliation to the United States, 30 December 2025, https://www.globenewswire.com/news-release/2025/12/30/3211650/0/en/AtaiBeckley-Completes-Redomiciliation-to-the-United-States.html
- Northdata, Atai Beckley N.V., Amstelveen (KvK 80299776), retrieved 18 September 2026, https://www.northdata.com/Atai+Beckley+N.V.,+Amstelveen/KVK+80299776
Get complete shareholder and officer records, ultimate beneficial owner resolution, and ongoing ownership monitoring.
Frequently Asked Questions
What does Atai Beckley N.V. do?
Clinical-stage biopharmaceutical company that developed psychedelic-inspired and related compounds for depression, anxiety and addiction, under the name ATAI Life Sciences N.V. until 5 November 2025.
Who owns Atai Beckley N.V.?
Nasdaq disclosure identified major institutional holders including Adage Capital Partners, Ally Bridge Group, ARK Investment Management, T. Rowe Price and Marshall Wace; full cap table not publicly disclosed.
Who is Atai Beckley N.V.'s UBO (Ultimate Beneficial Owner)?
No single ultimate beneficial owner identified; ownership was widely held among public-market institutional and retail investors typical of a Nasdaq-listed company.
What is Atai Beckley N.V.'s company registration number?
Atai Beckley N.V.'s registration number is 80299776, filed with Netherlands Chamber of Commerce (KvK) in Netherlands. Its current status on the register is inactive.
Is Atai Beckley N.V. still an active company?
Atai Beckley N.V.'s status on Netherlands Chamber of Commerce (KvK) is listed as inactive, not currently active.
What is Atai Beckley N.V.'s registered address?
The registered address on file for Atai Beckley N.V. is Amstelveen, Netherlands.
Is Atai Beckley N.V. listed on a stock exchange?
Ordinary shares listed on Nasdaq under ticker ATAI from June 2021; the Dutch entity converted into Delaware-incorporated AtaiBeckley Inc. on 30 December 2025, which now trades under the same ticker.
Who are the officers/directors of Atai Beckley N.V.?
Glenn Short, Ph.D. (Chief Scientific Officer) and Kevin Craig, M.D. (Chief Medical Officer) were confirmed via a company leadership announcement dated 10 January 2025.
Does Atai Beckley N.V. have a parent company or subsidiaries?
Ultimate parent of the atai corporate group; acquired Beckley Psytech Limited on 5 November 2025, then merged and converted into Delaware-incorporated AtaiBeckley Inc. on 30 December 2025.
Can Zavia monitor changes to Atai Beckley N.V.'s ownership over time?
This profile reflects a point-in-time snapshot from Netherlands Chamber of Commerce (KvK). Zavia's monitoring API can track changes to Atai Beckley N.V.'s registered shareholders, officers, and group structure going forward, flagging updates as they're filed rather than requiring a manual recheck.
Can I access Atai Beckley N.V.'s data through an API?
Yes. Zavia's API connects directly to official government ownership registries across 195 countries and territories, including Netherlands, so records like Atai Beckley N.V.'s registration, shareholder, UBO, and group-structure data can be queried programmatically instead of viewed one page at a time.
Where does this company information come from, and how current is it?
This record is sourced directly from Netherlands Chamber of Commerce (KvK) and was last synced on 18 September 2026.